About CuraTeQ Biologics
CuraTeQ Biologics is a company based in Hyderabad (India) founded in 2020. It operates as a B2B. The company has 424 employees as of March 31, 2023. CuraTeQ Biologics offers products and services including Trastuzumab Biosimilar, Denosumab Biosimilar, and Pegfilgrastim Biosimilar. CuraTeQ Biologics operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
- Headquarter Hyderabad, India
- Employees 424 as on 31 Mar, 2023
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Curateq Biologics Private Limited
- Date of Incorporation 25 Apr, 2020
- Jurisdiction Hyderabad, Telangana, India
-
Annual Revenue
$29.99 K (USD)-85.08as on Mar 31, 2023
-
Net Profit
-$66.14 M (USD)-76.32as on Mar 31, 2023
-
EBITDA
-$55.36 M (USD)-80.76as on Mar 31, 2023
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
424
as on Mar 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CuraTeQ Biologics
CuraTeQ Biologics offers a comprehensive portfolio of products and services, including Trastuzumab Biosimilar, Denosumab Biosimilar, and Pegfilgrastim Biosimilar.
Biosimilar for treating breast cancer and other tumors
Biosimilar for managing bone diseases and related conditions
Biosimilar to stimulate white blood cell production
Funding Insights of CuraTeQ Biologics
Detailed funding history for CuraTeQ Biologics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CuraTeQ Biologics
Investment portfolio details for CuraTeQ Biologics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CuraTeQ Biologics
Detailed financials for CuraTeQ Biologics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Curateq Biologics Comparisons
Peer comparison for CuraTeQ Biologics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CuraTeQ Biologics
CuraTeQ Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
Detailed competitors of CuraTeQ Biologics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Curateq Biologics
Complete news archive for CuraTeQ Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CuraTeQ Biologics
CuraTeQ Biologics was founded in 2020.
CuraTeQ Biologics is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
As of Mar 31, 2023, the latest employee count at CuraTeQ Biologics is 424.
Annual revenue of CuraTeQ Biologics is $29.99K as on Mar 31, 2023.
CuraTeQ Biologics focuses on developing and manufacturing biosimilars, particularly in oncology and immunology, using advanced facilities in Hyderabad, India. The company employs strategies like analytical biosimilarity and regulatory engagements to shorten development timelines and ensure high-quality, cost-effective products. They target global markets, including EU and emerging regions, to provide affordable therapies and improve health outcomes for patients suffering from debilitating illnesses.
CuraTeQ Biologics's top competitors include Moderna, BeiGene and Strand Therapeutics.
CuraTeQ Biologics offers Trastuzumab Biosimilar, Denosumab Biosimilar, and Pegfilgrastim Biosimilar.